Epitope of regulatory t cell surface antigen and antibody specifically binding thereto

A specific and antibody technology, applied in the direction of receptor/cell surface antigen/cell surface determinant, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody, etc.

Pending Publication Date: 2020-12-18
GOOD T CELLS INC
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no genes and proteins that can only target regulatory T cells alone

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Epitope of regulatory t cell surface antigen and antibody specifically binding thereto
  • Epitope of regulatory t cell surface antigen and antibody specifically binding thereto
  • Epitope of regulatory t cell surface antigen and antibody specifically binding thereto

Examples

Experimental program
Comparison scheme
Effect test

preparation Embodiment 1

[0125] [Preparation Example 1] T cell subtype cell culture

[0126] To identify whether Lrig-1 protein is expressed only in regulatory T (Treg) cells, T cell subsets Th0, Th1, Th2, Th17 and iTreg were prepared. Unlike naturally isolated nTregs, iTregs refer to cells artificially induced to differentiate in a medium having the following composition.

[0127] RPMI 1640 (Gibco, Grand Island, NY) nutrient medium containing 10% fetal bovine serum (FBS; HyClone, Logan, UT) was made further comprising the following Table 5 by first isolating naive T cells obtained from mouse spleen the individual components, and at 37°C, 5% CO 2 Cultured for 72 hours in an incubator to induce T cell subsets to differentiate into corresponding cells.

[0128] table 5

[0129] differentiated cells composition Th0 Anti-CD3, Anti-CD28 Th1 IL-12, anti-IL-4 antibodies Th2 IL-4, anti-IFNβ Th17 IL-6, TGFβ, anti-IFNβ, anti-IL-4 iTreg IL-2, TGFβ

Embodiment 1

[0130] [Example 1] Structural analysis of Lrig-1

[0131] Prediction of the three-dimensional structure of the extracellular domain of Lrig-1 protein to generate antibodies specific for Lrig-1 protein, a surface protein of regulatory T cells.

[0132] First, in order to predict the base sequence of the epitope, the tools of Uniprot (http: / / www.uniprot.org) and RCSB protein database (http: / / www.rcsb.org / pdb) were used to predict the Lrig-1 protein The three-dimensional structure of the extracellular domain (ECD) in order to identify the structure of the ECD. Then, the result is in figure 1 and 2 shown in .

[0133] Such as figure 1 As shown, there are a total of 15 leucine-rich regions, LRR1 to LRR15, in the Lrig-LRR domain (amino acid sequence at positions 41-494) of the extracellular domain of the Lrig-1 protein. Each LRR domain consists of 23-27 amino acids, of which 3 to 5 leucines are present.

[0134] Additionally, if figure 2 As shown, there are three immunog...

Embodiment 2

[0135] [Example 2] Identification of specific expression of Lrig-1 mRNA in regulatory T cells

[0136] It was verified whether Lrig-1 protein can be used as a specific biomarker of regulatory T cells.

[0137] For validation, CD4 beads were isolated from mouse spleens using magnetic-activated cell sorting (MACS). 4+ T cells. Subsequently, regulatory T (CD4 + cd 25+ T) cells and non-regulatory T (CD4 + cd 25- T) cells. For individual cells and cells differentiated in Preparative Example 1, mRNA was extracted using Trizol, and gDNA was removed from genomic RNA using a gDNA extraction kit (Qiagen) according to the manufacturer's protocol. The gDNA-deleted mRNA was synthesized into cDNA by BDsprint cDNA Synthesis Kit (Cloning Technologies).

[0138] Real-time polymerase chain reaction (RT PCR) was performed to quantitatively identify the expression level of Lrig-1 mRNA in the cDNA.

[0139]Using SYBR Green (Molecular Probes), according to the protocol provided by the manuf...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to an epitope of leucine-rich and immunoglobulin-like domains 1 (Lrig-1), which is an antigen present on the surface of a regulatory T cell, and an antibody or antigen-binding fragment specifically binding thereto.

Description

technical field [0001] The present invention relates to epitopes of leucine-rich and immunoglobulin-like domain 1 (Lrig-1) proteins, which are antigens present on the surface of regulatory T cells, and antibodies or antigen-binding fragments that specifically bind thereto . Background technique [0002] One of the most important characteristics in all normal individuals is the ability to recognize and eliminate non-self antigens without detrimental reactions to antigenic substances that constitute self. Thus, the failure of a living organism to respond to self-antigens is referred to as immunological anergy or tolerance. Self-tolerance occurs by eliminating lymphocytes that may have receptors specific for self-antigens, or by self-inactivation of responsiveness after exposure to self-antigens. Where there is a problem with the induction or maintenance of self-tolerance, an immune response to self-antigens occurs and the resulting disease is known as an autoimmune disease. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08C07K16/28A61K39/00
CPCC07K16/28A61K2039/505C07K2317/622C07K2317/21C07K2317/73C07K2317/34C07K2317/76C07K14/70503A61P35/00C07K7/08C07K7/06C07K16/2803
Inventor 金廷镐金范锡
Owner GOOD T CELLS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap